Bayne CE, Williams SB, Cooperberg MR, Gleave ME, Graefen M, Montorsi F et al (2016) Treatment of the primary tumor in metastatic prostate Cancer: current concepts and future perspectives. Eur Urol 69(5):775–787
Article
PubMed
Google Scholar
Breeuwsma AJ, Rybalov M, Leliveld AM, Pruim J, de Jong IJ (2012) Correlation of [11C]choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy. Q J Nucl Med Mol Imaging 56(5):440–446
PubMed
CAS
Google Scholar
Colombié M, Campion L, Bailly C, Rusu D, Rousseau T, Mathieu C et al (2015) Prognostic value of metabolic parameters and clinical impact of 18F-fluorocholine PET/CT in biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42(12):1784–1793
Article
PubMed
Google Scholar
Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F (2013) Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 63(6):1040–1048
Article
PubMed
Google Scholar
Giovacchini G, Incerti E, Mapelli P, Kirienko M, Briganti A, Gandaglia G et al (2015) [11C]choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 42(6):877–884
Article
PubMed
CAS
Google Scholar
Giovacchini G, Picchio M, Garcia-Parra R, Briganti A, Abdollah F, Gianolli L et al (2014) 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy. J Nucl Med 55(2):233–241
Article
PubMed
CAS
Google Scholar
Giovacchini G, Picchio M, Garcia-Parra R, Mapelli P, Briganti A, Montorsi F et al (2013) [11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen. J Urol 189(1):105–110
Article
PubMed
Google Scholar
Kjölhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T et al (2012) Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int 110(10):1501–1506
Article
PubMed
Google Scholar
Kjölhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T et al (2014) 18F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer. World J Urol 32(4):965–970
Article
PubMed
CAS
Google Scholar
Kjölhede H, Almquist H, Lyttkens K, Bratt O (2017) A population-based study of the clinical utility of 18F–choline PET/CT for primary metastasis staging of high-risk prostate cancer. Eur J Hybrid Imaging 1(1):12
Article
Google Scholar
Moschini M, Sharma V, Zattoni F, Quevedo JF, Davis BJ, Kwon E et al (2016) Natural history of clinical recurrence patterns of lymph node-positive prostate Cancer after radical prostatectomy. Eur Urol 69(1):135–142
Article
PubMed
Google Scholar
Osmonov DK, Aksenov AV, Trick D, Naumann CM, Hamann MF, Faddan AA et al (2016) Cancer-specific and overall survival in patients with recurrent prostate cancer who underwent salvage extended pelvic lymph node dissection. BMC Urol 16(1):56
Article
PubMed
PubMed Central
Google Scholar
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A et al (2018) Surveillance or metastasis-directed therapy for Oligometastatic prostate Cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446–453
Article
PubMed
Google Scholar
Pasqualetti F, Panichi M, Sainato A, Matteucci F, Galli L, Cocuzza P et al (2016) [18F]choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results. Radiat Oncol 11(1):9
Article
PubMed
PubMed Central
CAS
Google Scholar
Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ et al (2016) Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate Cancer. J Clin Oncol 34(24):2835–2842
Article
PubMed
CAS
Google Scholar
Seisen T, Vetterlein MW, Karabon P, Jindal T, Sood A, Nocera L et al (2017) Efficacy of local treatment in prostate Cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis. Eur Urol. https://doi.org/10.1016/j.eururo.2017.08.011;
Steuber T, Berg KD, Røder MA, Brasso K, Iversen P, Huland H et al (2017) Does Cytoreductive prostatectomy really have an impact on prognosis in prostate Cancer patients with low-volume bone metastasis? Results from a prospective case-control study. Eur Urol Focus 3(6):646–649
Article
PubMed
Google Scholar
Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D et al (2015) Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol 67(2):299–309
Article
PubMed
Google Scholar
Xie W, Regan MM, Buyse M, Halabi S, Kantoff P, Sartor O et al (2017) Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol 35(27):3097–3104
Article
PubMed
PubMed Central
Google Scholar
Zattoni F, Agostini E, Cattaneo F, Maruzzo M, Basso U, Zattoni F et al (2017) Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer. Clin Imaging 43:110–116
Article
PubMed
Google Scholar